RT Journal Article
SR Electronic
T1 Pre-COVID-19 humoral immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.14.20173393
DO 10.1101/2020.08.14.20173393
A1 Miyara, Makoto
A1 Sterlin, Delphine
A1 Anna, François
A1 Marot, Stéphane
A1 Mathian, Alexis
A1 Atif, Mo
A1 Quentric, Paul
A1 Mohr, Audrey
A1 Claër, Laetitia
A1 Parizot, Christophe
A1 Dorgham, Karim
A1 Yssel, Hans
A1 Chazal, Thibaud
A1 Fadlallah, Jehane
A1 Haroche, Julien
A1 Benameur, Neila
A1 Boutolleau, David
A1 Burrel, Sonia
A1 Mudumba, Sasi
A1 Hockett, Rick
A1 Gunn, Cary
A1 Charneau, Pierre
A1 Calvez, Vincent
A1 Marcellin, Anne-Geneviève
A1 Amoura, Zahir
A1 Gorochov, Guy
YR 2020
UL http://medrxiv.org/content/early/2020/08/15/2020.08.14.20173393.abstract
AB It is currently unknown whether acquired immunity to common alpha- and beta-coronaviruses provides cross-protection against SARS-CoV-2. In this study, we found that certain patient sera and intravenous immunoglobulins (IVIG) collected prior to the COVID-19 outbreak were cross-reactive to SARS-CoV-2 full-length Spike, S2 domain, and Nucleocapsid. However, their presence did not translate into neutralizing activity against SARS-CoV-2 in vitro. Importantly, we detected serum IgG reactivity to common coronaviruses in the early sera of patients with severe COVID-19 before the appearance of anti-SARS-CoV-2 antibodies. Collectively, the results of our study indicate that pre-existing immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2 in vivo.Competing Interest StatementM.M. received consulting fees from Genalyte Inc.Funding StatementMM and GG are supported by the Programme hospitalier de recherche clinique (PHRC: AOR17082,PHRCN 190321), DIM therapie genique Ile de France and AFPCA (Association Francaise de la PolyChondrite Atrophiante). D.S. was supported for this work by a Pasteur/APHP interface fellowship. The study was supported by Fondation de France, Tous unis contre le virus framework Alliance (Fondation de France, AP-HP, Institut Pasteur) in collaboration with Agence Nationale de la Recherche (ANR Flash COVID19 program), and by the SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University : ICOViD programs, PI: G.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CPP - Ile de France- VI at the Pitie-Salpetriere Hospital local ethical committee of Sorbonne Universite (n 2020-CER2020-21)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data are available in supplementary data or upon request